<p>隨着全球市場應對經濟變化的複雜性，亞洲股市為價值投資者提供了引人注目的機會。在波動的指數和不斷變化的經濟環境中，識別被低估的股票可能是利用潛在市場低效的關鍵。</p>
<h3>基於現金流的亞洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>廈門特寶生物（SHSE:688278）</td>
<td>CN¥82.99</td>
<td>CN¥165.09</td>
<td>49.7%</td>
</tr>
<tr>
<td>寶麗生物（TSE:4974）</td>
<td>¥919.00</td>
<td>¥1829.46</td>
<td>49.8%</td>
</tr>
<tr>
<td>蘇州澤爾根生物製藥（SHSE:688266）</td>
<td>CN¥113.00</td>
<td>CN¥223.99</td>
<td>49.6%</td>
</tr>
<tr>
<td>蘇州阿爾頓電氣與機械工業（SZSE:301187）</td>
<td>CN¥29.42</td>
<td>CN¥58.27</td>
<td>49.5%</td>
</tr>
<tr>
<td>南京宇宙化工（SZSE:300856）</td>
<td>CN¥14.28</td>
<td>CN¥28.44</td>
<td>49.8%</td>
</tr>
<tr>
<td>美圖（SEHK:1357）</td>
<td>HK$9.21</td>
<td>HK$18.02</td>
<td>48.9%</td>
</tr>
<tr>
<td>松屋 R&amp;D（TSE:7317）</td>
<td>¥731.00</td>
<td>¥1430.21</td>
<td>48.9%</td>
</tr>
<tr>
<td>Kolmar Korea（KOSE:A161890）</td>
<td>₩79000.00</td>
<td>₩155852.26</td>
<td>49.3%</td>
</tr>
<tr>
<td>HL Holdings（KOSE:A060980）</td>
<td>₩42150.00</td>
<td>₩83199.11</td>
<td>49.3%</td>
</tr>
<tr>
<td>安徽榮德科技（SHSE:688768）</td>
<td>CN¥49.18</td>
<td>CN¥97.08</td>
<td>49.3%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們基於現金流的 280 只被低估亞洲股票的完整列表。</p>
<p>讓我們更仔細地看看我們篩選出的幾隻股票。</p>
<h2>ASMPT（SEHK:522）</h2>
<p><strong>概述：</strong> ASMPT 有限公司是一家投資控股公司，涉及全球半導體和電子組裝行業的機器、工具和材料的設計、製造和營銷，市值約為 HK$295.7 億。</p>
<p><strong>運營：</strong> 公司的收入來自半導體解決方案，貢獻 HK$77.7 億，以及表面貼裝技術（SMT）解決方案，貢獻 HK$55.1 億。</p>
<p><strong>公允價值折扣估算：</strong> 44.3%</p>
<p>根據現金流，ASMPT 似乎被低估，當前交易價格為 HK$71，遠低於其估算的公允價值 HK$127.41。儘管最近在深圳進行了裁員以優化運營，但公司仍保持強勁的增長前景，預計年收益增長為 40.6%，超過香港市場的 12.2%。儘管利潤率從去年的 3% 降至 1.8%，ASMPT 的戰略調整旨在增強成本競爭力和運營韌性。</p>
<ul>
<li>我們的 ASMPT 增長報告中的分析暗示未來財務表現強勁。</li>
<li>點擊探索我們在 ASMPT 資產負債表健康報告中的詳細發現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d93ad6f1-2b1b-4cae-b992-0cc4eb72e03d/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d93ad6f1-2b1b-4cae-b992-0cc4eb72e03d/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>截至 2025 年 9 月的 SEHK:522 折現現金流</p>
<h2>新生鎮（SEHK:9911）</h2>
<p><strong>概述：</strong> 新生鎮有限公司是一家投資控股公司，全球運營社交網絡業務，市值為 HK$171.3 億。</p>
<p><strong>運營：</strong> 公司的收入來自兩個主要部門：創新業務，貢獻 CN¥6.031 億，以及社交網絡業務，貢獻 CN¥54 億。</p>
<p><strong>公允價值折扣估算：</strong> 29.5%</p>
<p>新生鎮的交易價格為 HK$12.76，低於其估算的公允價值 HK$18.09，突顯其基於現金流的低估。最近的收益顯示出強勁的表現，2025 年上半年淨收入達到 CNY 4.8928 億，較去年 CNY 2.2468 億有所增長。儘管最近董事會的變動可能影響戰略方向，但公司的年收益增長預期為 26.5%，超過香港市場的平均水平。</p>
<ul>
<li>根據我們的收益增長報告，有跡象表明新生鎮可能準備擴張。</li>
<li>點擊這裏訪問我們的完整資產負債表健康報告，以瞭解新生鎮的動態。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fcd5c300-fa92-45a8-85b8-008e7212a467/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fcd5c300-fa92-45a8-85b8-008e7212a467/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>截至 2025 年 9 月的 SEHK:9911 折現現金流</p>
<h2>Rorze（TSE:6323）</h2>
<p><strong>概述：</strong> Rorze 公司設計、開發、製造和銷售全球半導體和液晶顯示器生產的自動化系統，市值為¥3128.7 億。</p>
<p><strong>運營：</strong> 公司的收入來自全球半導體和液晶顯示器生產的自動化系統的設計、開發、製造和銷售。</p>
<p><strong>公允價值折扣估算：</strong> 34.2%</p>
<p>Rorze 的交易價格為¥1804，顯著低於其估算的公允價值¥2740.71。儘管利潤率從 23.4% 降至 15.7%，但公司仍然具有良好的價值，交易價格比公允價值估算低 34.2%。預計年收益將增長 15.81%，超過日本市場的平均水平 8.3%。最近完成的價值¥49.9994 億的股票回購計劃可能在高股價波動中提升股東價值。</p>
<ul>
<li>我們的綜合增長報告提出 Rorze 可能面臨顯著的財務增長機會。</li>
<li>點擊這裏閲讀我們的健康報告，深入瞭解 Rorze 的資產負債表。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4d659f8c-73ac-4638-abf7-18dec4e4fb14/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4d659f8c-73ac-4638-abf7-18dec4e4fb14/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>截至 2025 年 9 月的 TSE:6323 折現現金流</p>
<h2>讓它發生</h2>
<ul>
<li>點擊這裏訪問我們完整的 280 只基於現金流的被低估亞洲股票索引。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，您可以輕鬆監控所有股票的關鍵指標。</li>
<li>使用 Simply Wall St 應用程序提升您的投資能力，享受免費訪問涵蓋每個大洲的市場情報。</li>
</ul>
<h2>準備探索其他投資風格嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過穩健的分紅支付者來多樣化您的投資組合，以提供可靠的收入來源，以應對潛在的市場動盪。</li>
<li>充實您的投資組合，選擇那些顯示出強勁增長潛力的公司，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章並不構成財務建議。它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

特寶生物

00522

<p>亞洲股市為價值投資者提供了顯著的機會，因為他們正在應對經濟變化。根據現金流評估的前 10 只被低估股票名單中，包括廈門特寶生物和高橋生物，公允價值的折扣範圍在 48.9% 到 49.8% 之間。值得注意的還有 ASMPT 和 Newborn Town，這兩家公司均低於其估計的公允價值，顯示出增長潛力。分析師建議，這些股票可能會利用市場低效，使其成為投資的吸引選擇</p>

<p>As global markets navigate the complexities of economic shifts, Asian stock markets present intriguing opportunities for value investors. Amidst fluctuating indices and evolving economic landscapes, identifying stocks that are undervalued can be key to capitalizing on potential market inefficiencies.</p>
<div class="lb-trans"><p>隨着全球市場應對經濟變化的複雜性，亞洲股市為價值投資者提供了引人注目的機會。在波動的指數和不斷變化的經濟環境中，識別被低估的股票可能是利用潛在市場低效的關鍵。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基於現金流的亞洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Xiamen Amoytop Biotech (SHSE:688278)</td>
<td>CN¥82.99</td>
<td>CN¥165.09</td>
<td>49.7%</td>
</tr>
<tr>
<td>Takara Bio (TSE:4974)</td>
<td>¥919.00</td>
<td>¥1829.46</td>
<td>49.8%</td>
</tr>
<tr>
<td>Suzhou Zelgen Biopharmaceuticals (SHSE:688266)</td>
<td>CN¥113.00</td>
<td>CN¥223.99</td>
<td>49.6%</td>
</tr>
<tr>
<td>Suzhou Alton Electrical &amp; Mechanical Industry (SZSE:301187)</td>
<td>CN¥29.42</td>
<td>CN¥58.27</td>
<td>49.5%</td>
</tr>
<tr>
<td>Nanjing COSMOS Chemical (SZSE:300856)</td>
<td>CN¥14.28</td>
<td>CN¥28.44</td>
<td>49.8%</td>
</tr>
<tr>
<td>Meitu (SEHK:1357)</td>
<td>HK$9.21</td>
<td>HK$18.02</td>
<td>48.9%</td>
</tr>
<tr>
<td>Matsuya R&amp;DLtd (TSE:7317)</td>
<td>¥731.00</td>
<td>¥1430.21</td>
<td>48.9%</td>
</tr>
<tr>
<td>Kolmar Korea (KOSE:A161890)</td>
<td>₩79000.00</td>
<td>₩155852.26</td>
<td>49.3%</td>
</tr>
<tr>
<td>HL Holdings (KOSE:A060980)</td>
<td>₩42150.00</td>
<td>₩83199.11</td>
<td>49.3%</td>
</tr>
<tr>
<td>Anhui Ronds Science &amp; Technology (SHSE:688768)</td>
<td>CN¥49.18</td>
<td>CN¥97.08</td>
<td>49.3%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>廈門特寶生物（SHSE:688278）</td>
<td>CN¥82.99</td>
<td>CN¥165.09</td>
<td>49.7%</td>
</tr>
<tr>
<td>寶麗生物（TSE:4974）</td>
<td>¥919.00</td>
<td>¥1829.46</td>
<td>49.8%</td>
</tr>
<tr>
<td>蘇州澤爾根生物製藥（SHSE:688266）</td>
<td>CN¥113.00</td>
<td>CN¥223.99</td>
<td>49.6%</td>
</tr>
<tr>
<td>蘇州阿爾頓電氣與機械工業（SZSE:301187）</td>
<td>CN¥29.42</td>
<td>CN¥58.27</td>
<td>49.5%</td>
</tr>
<tr>
<td>南京宇宙化工（SZSE:300856）</td>
<td>CN¥14.28</td>
<td>CN¥28.44</td>
<td>49.8%</td>
</tr>
<tr>
<td>美圖（SEHK:1357）</td>
<td>HK$9.21</td>
<td>HK$18.02</td>
<td>48.9%</td>
</tr>
<tr>
<td>松屋 R&amp;D（TSE:7317）</td>
<td>¥731.00</td>
<td>¥1430.21</td>
<td>48.9%</td>
</tr>
<tr>
<td>Kolmar Korea（KOSE:A161890）</td>
<td>₩79000.00</td>
<td>₩155852.26</td>
<td>49.3%</td>
</tr>
<tr>
<td>HL Holdings（KOSE:A060980）</td>
<td>₩42150.00</td>
<td>₩83199.11</td>
<td>49.3%</td>
</tr>
<tr>
<td>安徽榮德科技（SHSE:688768）</td>
<td>CN¥49.18</td>
<td>CN¥97.08</td>
<td>49.3%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 280 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們基於現金流的 280 只被低估亞洲股票的完整列表。</p>
</div><p>Let's take a closer look at a couple of our picks from the screened companies.</p>
<div class="lb-trans"><p>讓我們更仔細地看看我們篩選出的幾隻股票。</p>
</div><h2>ASMPT (SEHK:522)</h2>
<div class="lb-trans"><h2>ASMPT（SEHK:522）</h2>
</div><p><strong>Overview:</strong> ASMPT Limited is an investment holding company involved in the design, manufacture, and marketing of machines, tools, and materials for the semiconductor and electronics assembly industries worldwide, with a market cap of approximately HK$29.57 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> ASMPT 有限公司是一家投資控股公司，涉及全球半導體和電子組裝行業的機器、工具和材料的設計、製造和營銷，市值約為 HK$295.7 億。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived from Semiconductor Solutions, contributing HK$7.77 billion, and Surface Mount Technology (SMT) Solutions, accounting for HK$5.51 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入來自半導體解決方案，貢獻 HK$77.7 億，以及表面貼裝技術（SMT）解決方案，貢獻 HK$55.1 億。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 44.3%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 44.3%</p>
</div><p>ASMPT appears undervalued based on cash flows, trading at HK$71, significantly below its estimated fair value of HK$127.41. Despite a recent downsizing in Shenzhen to optimize operations, the company maintains robust growth prospects with expected annual earnings growth of 40.6%, outpacing the Hong Kong market's 12.2%. While profit margins have decreased to 1.8% from last year's 3%, ASMPT's strategic realignment aims to enhance cost competitiveness and operational resilience.</p>
<div class="lb-trans"><p>根據現金流，ASMPT 似乎被低估，當前交易價格為 HK$71，遠低於其估算的公允價值 HK$127.41。儘管最近在深圳進行了裁員以優化運營，但公司仍保持強勁的增長前景，預計年收益增長為 40.6%，超過香港市場的 12.2%。儘管利潤率從去年的 3% 降至 1.8%，ASMPT 的戰略調整旨在增強成本競爭力和運營韌性。</p>
</div><ul>
<li>The analysis detailed in our ASMPT growth report hints at robust future financial performance.</li>
<li>Click to explore a detailed breakdown of our findings in ASMPT's balance sheet health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們的 ASMPT 增長報告中的分析暗示未來財務表現強勁。</li>
<li>點擊探索我們在 ASMPT 資產負債表健康報告中的詳細發現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d93ad6f1-2b1b-4cae-b992-0cc4eb72e03d/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/d93ad6f1-2b1b-4cae-b992-0cc4eb72e03d/chart/dcf?theme=light"/></p>
<p>SEHK:522 Discounted Cash Flow as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SEHK:522 折現現金流</p>
</div><h2>Newborn Town (SEHK:9911)</h2>
<div class="lb-trans"><h2>新生鎮（SEHK:9911）</h2>
</div><p><strong>Overview:</strong> Newborn Town Inc. is an investment holding company that operates in the social networking business globally, with a market cap of HK$17.13 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 新生鎮有限公司是一家投資控股公司，全球運營社交網絡業務，市值為 HK$171.3 億。</p>
</div><p><strong>Operations:</strong> The company generates revenue from two main segments: Innovative Business, contributing CN¥603.10 million, and Social Networking Business, which accounts for CN¥5.40 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入來自兩個主要部門：創新業務，貢獻 CN¥6.031 億，以及社交網絡業務，貢獻 CN¥54 億。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 29.5%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 29.5%</p>
</div><p>Newborn Town is trading at HK$12.76, below its estimated fair value of HK$18.09, highlighting its undervaluation based on cash flows. Recent earnings show a strong performance with net income reaching CNY 489.28 million for the first half of 2025, up from CNY 224.68 million the previous year. The company's projected annual earnings growth of 26.5% surpasses the Hong Kong market average, despite recent board changes that may impact strategic direction.</p>
<div class="lb-trans"><p>新生鎮的交易價格為 HK$12.76，低於其估算的公允價值 HK$18.09，突顯其基於現金流的低估。最近的收益顯示出強勁的表現，2025 年上半年淨收入達到 CNY 4.8928 億，較去年 CNY 2.2468 億有所增長。儘管最近董事會的變動可能影響戰略方向，但公司的年收益增長預期為 26.5%，超過香港市場的平均水平。</p>
</div><ul>
<li>According our earnings growth report, there's an indication that Newborn Town might be ready to expand.</li>
<li>Click here and access our complete balance sheet health report to understand the dynamics of Newborn Town.</li>
</ul>
<div class="lb-trans"><ul>
<li>根據我們的收益增長報告，有跡象表明新生鎮可能準備擴張。</li>
<li>點擊這裏訪問我們的完整資產負債表健康報告，以瞭解新生鎮的動態。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fcd5c300-fa92-45a8-85b8-008e7212a467/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/fcd5c300-fa92-45a8-85b8-008e7212a467/chart/dcf?theme=light"/></p>
<p>SEHK:9911 Discounted Cash Flow as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SEHK:9911 折現現金流</p>
</div><h2>Rorze (TSE:6323)</h2>
<div class="lb-trans"><h2>Rorze（TSE:6323）</h2>
</div><p><strong>Overview:</strong> Rorze Corporation designs, develops, manufactures, and sells automation systems for semiconductor and flat panel display production globally, with a market cap of ¥312.87 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Rorze 公司設計、開發、製造和銷售全球半導體和液晶顯示器生產的自動化系統，市值為¥3128.7 億。</p>
</div><p><strong>Operations:</strong> The company generates revenue from the design, development, manufacture, and sale of automation systems for semiconductor and flat panel display production globally.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入來自全球半導體和液晶顯示器生產的自動化系統的設計、開發、製造和銷售。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 34.2%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 34.2%</p>
</div><p>Rorze, trading at ¥1804, is significantly undervalued compared to its estimated fair value of ¥2740.71. Despite a decline in profit margins from 23.4% to 15.7%, the company remains a good value, trading 34.2% below fair value estimates. Earnings are forecasted to grow annually by 15.81%, outpacing the Japanese market average of 8.3%. Recent completion of a share buyback program worth ¥4,999.94 million may enhance shareholder value amidst high share price volatility.</p>
<div class="lb-trans"><p>Rorze 的交易價格為¥1804，顯著低於其估算的公允價值¥2740.71。儘管利潤率從 23.4% 降至 15.7%，但公司仍然具有良好的價值，交易價格比公允價值估算低 34.2%。預計年收益將增長 15.81%，超過日本市場的平均水平 8.3%。最近完成的價值¥49.9994 億的股票回購計劃可能在高股價波動中提升股東價值。</p>
</div><ul>
<li>Our comprehensive growth report raises the possibility that Rorze is poised for substantial financial growth.</li>
<li>Get an in-depth perspective on Rorze's balance sheet by reading our health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們的綜合增長報告提出 Rorze 可能面臨顯著的財務增長機會。</li>
<li>點擊這裏閲讀我們的健康報告，深入瞭解 Rorze 的資產負債表。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4d659f8c-73ac-4638-abf7-18dec4e4fb14/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/4d659f8c-73ac-4638-abf7-18dec4e4fb14/chart/dcf?theme=light"/></p>
<p>TSE:6323 Discounted Cash Flow as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 TSE:6323 折現現金流</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>讓它發生</h2>
</div><ul>
<li>Click here to access our complete index of 280 Undervalued Asian Stocks Based On Cash Flows.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們完整的 280 只基於現金流的被低估亞洲股票索引。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，您可以輕鬆監控所有股票的關鍵指標。</li>
<li>使用 Simply Wall St 應用程序提升您的投資能力，享受免費訪問涵蓋每個大洲的市場情報。</li>
</ul>
</div><h2>Ready To Venture Into Other Investment Styles?</h2>
<div class="lb-trans"><h2>準備探索其他投資風格嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過穩健的分紅支付者來多樣化您的投資組合，以提供可靠的收入來源，以應對潛在的市場動盪。</li>
<li>充實您的投資組合，選擇那些顯示出強勁增長潛力的公司，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章並不構成財務建議。它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

亞洲價值股在 2025 年 9 月提供的預期機會